• linkedin
  • Increase Font
  • Sharebar

    Researchers target potent HIV antibodies in new study


    Powerful discovery

    Barton F. Haynes, MD, director of the Duke Human Vaccine Institute, the Frederic M. Hanes professor of medicine and immunology at Duke University Medical Center in Durham, North Carolina, and the lead author of the report said the study reveals for the first time how plasma antibodies form—a discovery that could lead to preventive vaccines and curative treatments for HIV.

    “We isolated many of these unusual antibodies that were in the same family so that we can have for the first time the pathway of how they developed,” Haynes recently told Medical Economics.
    Haynes said the mixtures of the genes of the B cell and plasma antibodies revealed a chimeric antibody that was more potent than most previously isolated.

    “We are now developing this and related antibodies in forms that can be used to ferret out hidden virus infected CD4 T cells in HIV infected individuals,” Haynes said.

    If successful, the discovery would make the constructed antibody the most potent HIV antibody found to date.

    While the research is still in the early stages, Haynes said he hopes his team’s work will lead to the development of both preventive vaccines and curative treatments for HIV. First, more work would need to be done to further develop the antibody, and the team would obtain federal approval for further testing. Haynes said the study could contribute to work investigating holistic treatments that utilize broadly neutralizing antibodies to find HIV cells and point killer T cells in their direction.



    Rachael Zimlich, RN
    Ms Zimlich is a freelance writer in Cleveland, Ohio. She writes regularly for Contemporary Pediatrics, Managed Healthcare Executive, and ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow